Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved a new drug application (NDA) for Gilead Sciences' Viread (tenofovir disoproxil fumarate), an oral powder in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients.
Subscribe to our email newsletter
Aptalis Pharma and Gilead have co-developed the oral powder formulation of Viread using the Aptalis Microcaps taste-masking technology.
The Aptalis microencapsulation technology, known as Microcaps, employs versatile and precise coating techniques to encapsulate individual drug particles using solvent- and aqueous-based coacervation.
Gilead will be responsible for the product commercialization, while Aptalis will manufacture and supply the oral powder to Gilead.